The effect of co-processed dry binder with microcrystalline cellulose on release of verapamil hydrochloride from hydrophilic matrix tablets

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216275%3A25310%2F18%3A39913360" target="_blank" >RIV/00216275:25310/18:39913360 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/18:10382391

Výsledek na webu

<a href="http://dx.doi.org/10.32383/appdr/85701" target="_blank" >http://dx.doi.org/10.32383/appdr/85701</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.32383/appdr/85701" target="_blank" >10.32383/appdr/85701</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The effect of co-processed dry binder with microcrystalline cellulose on release of verapamil hydrochloride from hydrophilic matrix tablets

Popis výsledku v původním jazyce

The aim of this study was to evaluate the use of co-processed dry binder MicroceLac100 (lactose and microcrystalline cellulose in ratio 3 : 1) and Comprecel 102 (pure microcrystalline cellulose) in formulations for the extended release of verapamil hydrochloride. Hydrophilic matrix tablets containing verapamil hydrochloride, hypromellose and dry binder were prepared by the direct compression method. Hypromelloses MethocelTM K4M Premium CR or MethocelTM K100M Premium CR were used as controlled release agents. Using scanning electron microscopy regular distribution of the active substance in the prepared tablets was confirmed. Release of verapamil hydrochloride from the prepared formulations was studied by the dissolution test method. The dissolution profiles were fitted to the first-order kinetic model, Higuchi diffusion model, Korsmeyer-Peppas and Weibull model and kinetic parameters as the first order release rate constant (k1), release exponent (n) from Korsmeyer-Peppas model, Higuchi constant (KH) and parameters of Weibull model (b, λ) were determined. Based on the results of non-linear regression analysis, the higher release rate constants were found for formulations containing co-processed dry binder MicroceLac100 in comparison with formulations containing pure microcrystalline cellulose (Comprecel 102). In addition, tablets swelling, erosion and disintegration during the dissolution test were monitored photographically.

Název v anglickém jazyce

The effect of co-processed dry binder with microcrystalline cellulose on release of verapamil hydrochloride from hydrophilic matrix tablets

Popis výsledku anglicky

The aim of this study was to evaluate the use of co-processed dry binder MicroceLac100 (lactose and microcrystalline cellulose in ratio 3 : 1) and Comprecel 102 (pure microcrystalline cellulose) in formulations for the extended release of verapamil hydrochloride. Hydrophilic matrix tablets containing verapamil hydrochloride, hypromellose and dry binder were prepared by the direct compression method. Hypromelloses MethocelTM K4M Premium CR or MethocelTM K100M Premium CR were used as controlled release agents. Using scanning electron microscopy regular distribution of the active substance in the prepared tablets was confirmed. Release of verapamil hydrochloride from the prepared formulations was studied by the dissolution test method. The dissolution profiles were fitted to the first-order kinetic model, Higuchi diffusion model, Korsmeyer-Peppas and Weibull model and kinetic parameters as the first order release rate constant (k1), release exponent (n) from Korsmeyer-Peppas model, Higuchi constant (KH) and parameters of Weibull model (b, λ) were determined. Based on the results of non-linear regression analysis, the higher release rate constants were found for formulations containing co-processed dry binder MicroceLac100 in comparison with formulations containing pure microcrystalline cellulose (Comprecel 102). In addition, tablets swelling, erosion and disintegration during the dissolution test were monitored photographically.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Poloniae Pharmaceutica - Drug Research

ISSN

0001-6837

e-ISSN

—

Svazek periodika

75

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

9

Strana od-do

1223-1231

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85056238070